AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Among AstraZeneca’s various therapeutic areas, Oncology product sales were up 22%, while Cardiovascular, Renal and Metabolism ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

The adjusted EPS was $2.08 (1 ADR = 2 Common Shares). AstraZeneca’s top business, oncology, increased 19% (up 22% on constant ...

The company produces and commercializes medicines for cancer, gastrointestinal, cardiovascular, neuroscience, oncology, respiratory and inflammation and other infectious diseases. Read More on AZN: ...

AstraZeneca plans a new investment of $2 billion in the U.S., one of the first major foreign companies to shift spending to ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...

Oncology Total Revenue (First Nine Months 2024): $16 billion ... Full Year Guidance Upgrade (2024): Total revenue and core ...